Advertisement
Canada markets close in 6 hours 5 minutes
  • S&P/TSX

    22,011.95
    +0.23 (+0.00%)
     
  • S&P 500

    5,084.91
    +14.36 (+0.28%)
     
  • DOW

    38,501.49
    -2.20 (-0.01%)
     
  • CAD/USD

    0.7299
    -0.0021 (-0.29%)
     
  • CRUDE OIL

    82.90
    -0.46 (-0.55%)
     
  • Bitcoin CAD

    90,738.42
    -356.23 (-0.39%)
     
  • CMC Crypto 200

    1,428.66
    +4.56 (+0.32%)
     
  • GOLD FUTURES

    2,335.40
    -6.70 (-0.29%)
     
  • RUSSELL 2000

    2,003.40
    +0.76 (+0.04%)
     
  • 10-Yr Bond

    4.6340
    +0.0360 (+0.78%)
     
  • NASDAQ

    15,811.79
    +115.15 (+0.73%)
     
  • VOLATILITY

    15.70
    +0.01 (+0.06%)
     
  • FTSE

    8,064.05
    +19.24 (+0.24%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6823
    -0.0013 (-0.19%)
     

Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8b

Last week, IVERIC bio, Inc. (NASDAQ:ISEE) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 4.0% last week, resulting in a US$107m increase in the company's market worth. As a result, their original purchase of US$241k worth of stock is now worth US$511k.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for IVERIC bio

The Last 12 Months Of Insider Transactions At IVERIC bio

In the last twelve months, the biggest single purchase by an insider was when Independent Director Calvin Roberts bought US$241k worth of shares at a price of US$9.62 per share. We do like to see buying, but this purchase was made at well below the current price of US$20.45. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

ADVERTISEMENT

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

IVERIC bio is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does IVERIC bio Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.5% of IVERIC bio shares, worth about US$14m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About IVERIC bio Insiders?

The fact that there have been no IVERIC bio insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in IVERIC bio and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing IVERIC bio. Case in point: We've spotted 3 warning signs for IVERIC bio you should be aware of, and 1 of these is potentially serious.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here